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FOREWORD 
The fifth series of reports of the Scientific Committee for Animal Nutri-
tion (1) contains the opinions expressed by the Committee in the period 
between 23 November 1983 and 26 September 1985. As in the past, the 
opinions are based on scrupulous evaluations involving research in many 
scientific fields and the very latest expert knowledge. 
At the Committee's request, most of the additives were subjected to 
additional investigations deemed essential before any judgment could be 
pronounced. Detailed answers could thus be given to the various ques-
tions put by the Commission. 
In addition, the Committee worked in close collaboration with the Scien-
tific Committee for Food (2) to examine the effects of the use of protein 
products obtained by growing bacteria on methanol and yeast on alkanes 
for animal feeding. These studies and opinions provide essential in-
formation for the legislative authorities as well as being of topical in-
terest to all who are concerned by the application of new biotechnologies 
in livestock production. 
(1) Previous series were published by the Office for Official Publica-
tions of the European Communities, Luxembourg, as follows : 
1st series (1979) 
2nd series (1980) 
3rd series (1981) 
4th series (1984) 
Catalogue No CB-28-79-27 7 
No EUR 6918 
No EUR 7383 
No EUR 8769 
(2) The composition of the Committee was published in OJ No C 272, 
11.10.1983, p. 2 
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SECOND REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF MONENSIN SODIUM IN FEEDINGSTUFFS FOR TURKEYS 
Opinion expressed 23 November 1983 
TERMS OF REFERENCE (July 1980) 
In reply to questions put by the Commission on the safety of use of mone-
nsin sodium in feedingstuffs for turkeys, the Committee, in its report of 
11 March and 9 December 1981 (*), considered that it could not express an 
opinion because of a lack of data on the metabolism of monensin in 
turkeys and on the nature and fate of its excretion products. 
As the studies requested have been carried out and are now available, the 
Committee expressed the following opinion. 
OPINION OF THE COMMITTEE 
1. Tissue residues were determined in turkeys using monensin labelled 
14 with C at seven specific sites. Birds were fed 110 mg labelled 
monensin/kg feed for five days and sacrified 6 hours after treatment, 
thus allowing equilibration of tissue levels at steady state turn-
over. Residues ranged from about 1 mg/kg in the liver to less than 
0.2 mg/kg in kidney, skin and fat, and less than 0.05 mg/kg in muscle 
(limit of detection 0.03 mg/kg). These results are comparable to 
14 those found in chicken using similar C-labelled material. The 
distribution of the metabolites in the liver and excreta was also 
examined and found to mimic the chicken data. 
(*) Reports of the Scientific Committee for Animal Nutrition, fourth 
series (1984), No EUR 8769, p. 25 
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Examination of the radioactive residues in the liver showed that 
about 1% of the total hepatic radioactivity was due to unchanged 
monensin, the remainder being distributed among the hepatic metaboli-
ties. Similarly, 7-8% of the total radioactivity in the excreta was 
represented by unchanged monensin, the rest being distributed among 
numerous faecal metabolites. The chromatographic pattern of the 
metabolites in faeces and liver appeared to be similar to that of the 
chicken, the main hepatic metabolite in both species being O-demethy-
lated monensin. This compound has only 5% of the physiological acti-
vity of monensin. 
Another residue study using turkeys fed for 17 weeks on 110 mg un-
labelled monensin/kg feed gave results lower than those of the pre-
vious studies in liver, skin and kidney after 24 hours and no detect-
able residues after 48 hours. Analysis was carried out by microbio-
logical assay (limit of detection 0.025 mg/kg tissue). 
The use of monensin sodium up to the level of 110 ppm in the feeding-
stuffs for turkeys would thus not lead to any measurable residues in 
the treated birds, provided a withdrawal period of at least three 
days is observed. 
14 2. A comparison of the studies using both C-labelled and unlabelled 
monensin in chickens and turkeys reveals quantitative and qualitative 
similarities with regard to metabolite pattern and tissue residue le-
vels . It may therefore be assumed that the data concerning the bio-
degradation of monensin and monensin metabolites from chicken excreta 
in soil and water are also valid for the same substances derived from 
turkey excreta. 
Environmental effects were studied using excreta from chicken or 
steers. Chicken fed 120 ppm monensin in their feed for 90 days ex-
creted between 1.2 - 3.6 ppm (wet basis) in the faeces. When chicken 
excreta were stored, the monensin content dropped to 15% within 4 
days. The monensin content of manure from steers declined to 20% 
within 9 weeks and of faeces to 65% within 10 weeks. 
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Monensin degrades in soil within 4 weeks. It leaches only from sandy 
soils, 30% being recovered in the leachate. Monensin slowly degrades 
in water on exposure to light with a half-life of over 30 days. 
Litter from broilers containing about 3 ppm was not phytotoxic to 14 
plant species when applied at the rate of 10 tons/ha. Cattle manure 
containing 2.8 ppm monensin was not toxic to earth worms (Eisenia 
foetida). Concentrations of monensin up to 300 ppm produced no appa-
rent toxicity in rainbow trout (Salmo sairdneri) treated for 14 
days. The acute LD for bluegills (Lepomis macrochirus) was 
33 ppm. 
Monensin activity disappeared from activated sludge within 4 days and 
up to 25 mg/ml had no effect on the 5 day biochemical oxygen demand. 
Addition of pure monensin inhibits methane production in biogas pro-
duction and also pure cultures of methanogenic bacteria. This acti-
vity is in agreement with the reduction in methane production obser-
ved in the rumen. 
The use of monensin sodium in feedingstuffs for turkeys is thus not 
prejudicial to the environment. 
On the basis of the available data, the Committee is of the opinion 
that the proposed conditions of use of monensin sodium in feeding-
stuffs for turkeys are acceptable, subject to a limitation of the 
maximum content to 110 mg/kg feedingstuff and provided a withdrawal 
period of at least 3 days is observed. However, the concentration 
resulting in maximum efficacy does not exceed 100 mg/kg. 
REFERENCES 
Dossiers supplied by Lilly Research Centre Ltd. (1983) 
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SECOND REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF NARASIN IN FEEDINGSTUFFS FOR CHICKENS 
Opinion expressed 8 February 1984 
TERMS OF REFERENCE (November 1980) 
In reply to questions put by the Commission on the safety of use of nara-
sin in feedingstuffs for chickens, the Committee, in its report of 
14 April 1982 (*), considered that the proposed use could be admitted 
provisionally with a withdrawal period of at least five days before 
slaughter and that a reassessment would be envisaged when full data on 
the metabolism of narasin in chickens become available. 
As additional studies have been carried out on the identity, the micro-
biological and biochemical activity of the major metabolites, and on the 
fate of tissue residues in chickens, the Committee expressed the follow-
ing opinion. 
OPINION OF THE COMMITTEE 
. . . 14 
1. Additional studies using narasin labelled with C at several spe-
cific sites of the molecule confirmed that hydroxylation is the pri-
mary mode of narasin metabolism in chicken and that, among the six 
major metabolites isolated from chicken excreta, four are dihydroxy-
and two trihydroxynarasins. Microbiological assays showed that these 
metabolites are 20 times less active than narasin on Bacillus sub-
tilis. Individual biochemical testing of four of them (three dihy-
droxy- and one trihydroxynarasin) on rat liver cell mitochondria 
showed that they are much less effective than narasin in producing 
ionophorous effects. 
(*) Reports of the Scientific Committee for Animal Nutrition, fourth 
series (1984), No EUR 8769, p. 41 
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Additional studies on tissue residues were carried out in chickens 
14 fed 100 mg C-narasin/kg feedingstuff for five days. All residue 
levels decreased by more than 50% during the first day withdrawal. 
After three days withdrawal, the total radioactive residues, 
expressed as narasin, were of the order of 0.1 mg/kg in liver, 
0.03 mg/kg in kidney and skin and 0.01 mg/kg in fat and muscle. 
These levels had slightly decreased after five days withdrawal. 
A chromatographic separation completed with a bioautographic assay 
showed that residues in liver, kidney and muscle contained no un-
changed narasin (limit of detection : 0.005 mg/kg) and that the 
small amounts of unchanged narasin in fat and skin had disappeared 
after two days withdrawal. 
3. On the basis of these data, the Committee is of the opinion that the 
use of narasin can be admitted without risks in feedingstuffs for 
chickens at the levels provisionally authorized (60 - 80 mg/kg) and 
with a withdrawal period of at least five days before slaughter. 
REFERENCES 
Dossiers Lilly Research Centre Ltd. (1983) 
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THIRD REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF HALOFUGINONE IN FEEDINGSTUFFS FOR POULTRY 
Opinion expressed 8 February 1984 
TERMS OF REFERENCE (November 197 7 and October 1981) 
In reply to questions put by the Commission on the safety of use of halo-
fuginone in feedingstuffs for chickens and turkeys, the Committee, in its 
reports of 25 April 1979 (*) and 17 November 1982 (**), considered that 
the proposed uses could be admitted provisionally with a withdrawal pe-
riod of at least seven days before slaughter and that further information 
was necessary to issue a final opinion. 
As the additional studies requested on the biodegradation of the product 
in the environment had been carried out, and assessed by the Committee in 
1982 (**) , alone some toxicological aspects of halofuginone needed to be 
clarified. As new experimental data on this topic are now available, the 
Committee expressed the following opinion. 
OPINION OF THE COMMITTEE 
The Committee has reviewed the results of four additional mutagenicity 
tests requested to clarify whether or not halofuginone had any genotoxic 
potential. 
(*) Reports of the Scientific Committee for Animal Nutrition, second 
series (1980), No EUR 6918, p. 11 
(**) Reports of the Scientific Committee for Animal Nutrition, fourth 
series (1984), No EUR 8769, p. 94 
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The in vitro point mutation test in cultured mouse lymphoma cells strain 
L 51784 Y was negative both in the presence and absence of S 9 mix for 
metabolic activation. The in vivo bone marrow cytogenetics test in the 
rat showed no clastogenic effects in this species. An in vitro test for 
DNA repair synthesis in HeLa 53 epithelioid cells, using radiolabelled 
thymidine incorporation and autoradiography, gave erratic results which 
were not repeatable. Because of a vague indication that halofuginone 
might induce some DNA repair synthesis directly in the absence of S 9 
mix, a test for covalent binding of halofuginone to the hepatic DNA of 
rats was carried out. Practically no covalent binding was detected. 
In the light of these findings, the Committee considered that halofugi-
none had no genotoxic activity nor any mutagenic potential. This com-
pound can be admitted without risks in feedingstuffs for chickens and 
turkeys at the levels provisionally authorized (2-3 mg/kg) and with a 
withdrawal period of at least five days before slaughter. 
REFERENCES 
HRC Reports PSL 563/83976, 564/82723, 64/83730 
IBMC Report 0333-83 
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SECOND REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF SALINOMYCIN IN FEEDINGSTUFFS FOR CHICKENS 
Opinion expressed 4 April 1984 
TERMS OF REFERENCE (November 1980) 
In reply to questions put by the Commission on the safety of use of sali-
nomycin in feedingstuffs for chickens, the Committee expressed a favoura-
ble opinion on 14 April 1982 (*) on the provisional use of the additive 
in feedingstuffs for chickens, piglets, pigs and fattening cattle, sub-
ject to a withdrawal period of five days before slaughter. It was agreed 
that the product should be reassessed when additional data on the nature 
of tissue metabolites in the various species were available. 
In the light of the information that has since been received on the use 
of the additive for chickens it is possible to interpret the original 
data more accurately. Accordingly, the Committee's opinion is now as 
follows. 
OPINION OF THE COMMITTEE 
1. The metabolism of salinomycin has been studied in the chicken, using 
14 a molecule labelled with C at three specific sites, including one 
corresponding to the carboxylic function. After administration of 
single or multiple oral doses, most (up to 97%) of the radioactivity 
was recovered in the excreta within 72 hours. Almost all the activi-
ty was detected in the intestinal and caecal contents, showing that 
excretion via the urine is of limited significance. 
(*) Reports of the Scientific Committee for Animal Nutrition, fourth 
series (1984), No EUR 8769, p. 36 
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Measurable quantities of radioactivity (14% of the ingested dose) 
were excreted over a 72 hours period in the bile, indicating that 
salinomycin is partially absorbed. However, the very low levels mea-
sured in the blood and their limited persistence therein (1 hour) in-
dicated that the salinomycin that is absorbed returns mainly to the 
intestine via the bile after metabolism in the liver. A very low ex-
14 cretion of CO was observed. 
Analysis of the excreted products showed the presence of a very small 
quantity of the unchanged antibiotic (< 1%) and a number of metaboli--
tes, of which the three main ones have been identified. One is a 
di-hydroxylated derivative and two are tri-hydroxylated, representing 
11% and 28% respectively of the excreted radioactivity. Chromatogra-
phic analyses showed the presence of the same metabolites in the 
bile. It can be established from these data that salinomycin once 
absorbed is metabolized and that the metabolites are eliminated 
mainly via the bile and subsequently via the faeces. There was no 
qualitative or quantitative difference between males and females. 
Metabolites recovered from the excreta have a much lower antibiotic 
activity and acute toxicity (mouse) than salinomycin itself. 
2. Following administration of salinomycin at the level of 66 g/ton of 
feedingstuff for 10 days and after a withdrawal period of 24 hours no 
antibiotic activity was detected in the chicken tissues (microbiolo-
gical limit of detection, expressed as salinomycin : 0.01 mg/kg). 
In another experiment covering 28 days of administration at dose-
levels between 80 and 140 g/ton of feedingstuff, an antibiotic acti-
vity was measured after 17 hours withdrawal of salinomycin in the li-
ver and kidneys (0.05 mg/kg, expressed as salinomycin) and subcuta-
neous fat (0.05 - 1 mg/kg, expressed as salinomycin). After 72 hours 
withdrawal, there was no more activity except in the liver of one 
animal where traces were detected. Under the same experimental con-
. . 14 
ditions, the use of C-salinomycin showed measurable residual 
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radioactivity in the liver, kidneys, muscle and adipose tissue 120 
hours after cessation of administration. In further investigations 
salinomycin was identified in the adipose tissue and the liver after 
a withdrawal period of 17 hours, together with labelled trigly-
cerides. After longer withdrawal periods (72 and 120 h), the resi-
dual radioactivity in adipose tissue and skin was mostly present in 
the lipids and resulted from the incorporation of labelled carbon 
fragments arising from the salinomycin molecule. It is likely that 
the insoluble radioactive fraction simultaneously present in the 
liver and kidneys has a similar origin. 
3. On the basis of the available data, the Committee is of the opinion 
that salinomycin can be used without risks in feedingstuffs for 
chickens at the level provisionally authorized (50 - 70 mg/kg) and 
with a withdrawal period of not less than five days before slaughter. 
REFERENCES 
Dossiers Hoechst A.G. (1983) 
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SECOND REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF OLAQUINDOX IN FEEDINGSTUFFS FOR PIGS 
Opinion expressed 3 May 1984 
TERMS OF REFERENCE (July 1978) 
In reply to questions put by the Commission on the safety of use of 
olaquindox in feedingstuffs for pigs, the Committee, in its report of 
8 July 1981 (*), considered that the proposed use could be admitted pro-
visionally and that a reassessment would be necessary once additional 
data on mutagenicity become available. The Committee noted that the 
mutagenicity studies then available appreared to be insufficient and re-
quested further extensive studies using a battery of tests covering not 
only bacterial test systems but also those investigating other genetic 
endpoints in relation to chromosomal and DNA changes. 
As the studies requested have been carried out and are now available, the 
Committee expressed the following opinion. 
OPINION OF THE COMMITTEE 
1. The Committee reviewed a total of 15 mutagenicity tests covering the 
following genetic endpoints : point mutations in prokaryotes and 
eukaryotes in vitro and in vivo, cytogenetic changes in vitro and 
in vivo, the latter by several routes of administration, and reaction 
with DNA. Practically all in vitro and in vivo tests were positive 
but only at near toxic doses. Covalent binding to DNA and those 
tests in mice, where the dosage used was low, were negative. The 
mouse appears to be comparatively insensitive to olaquindox yet most 
of the mutagenicity tests were performed in this species. 
(*) Reports of the Scientific Committee for Animal Nutrition, fourth 
series (1984), No EUR 8769, p. 1 
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However, a test for clastogenic potential in the Chinese hamster, a 
sensitive species, was positive. These findings show that olaquindox 
is genotoxic. It has no carcinogenic potential as determined in 
long-term studies. 
2. Possible risks from dust inhalation were also studied. Feedingstuffs 
containing 50 mg olaquindox/kg feed were tested both in meal and 
pellet form under normal feeding conditions, the process of preparing 
the feed from premix containing olaquindox not having been examined 
for dust development. Feeding proceeded by distributing either 2 
batches of meal or 1 batch of pellets to 5 pens over a period of 3 
minutes. Air was sampled throughout the whole feeding period at the 
height and in the neighbourhood of the operator using an Andersen-
Mark II-Cascade impactor. No olaquindox was detected on the filters 
or in the 24-hour urine sample of the operator. These findings con-
firm the opinion of the Committee stated earlier, that the risk to 
health incurred by farm workers is negligible under practical condi-
tions of distribution of animal feed containing olaquindox. 
3. The Committee recalls that residues resulting from the use of ola-
quindox in pig feed are below the detection limits after 48 hours 
withdrawal (limit of detection 0.1 mg/kg). 
4. In the light of these data, the Committee is of the opinion that ola-
quindox fulfilling the specifications of the preparation investigated 
can be used without risks in feedingstuffs for pigs up to four months 
at the levels provisionally authorized (15-50 mg/kg of complete 
feedingstuffs; 50-100 mg/kg of milk replacers) and with a withdrawal 
period of at least four weeks before slaughter. 
REFERENCES 
Supplementary Dossiers Bayer A.G. (1983, 1984) 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF PANCOXIN (*) AND PANCOXIN PLUS (*) 
IN FEEDINGSTUFFS FOR POULTRY 
Opinion expressed 3 May 1984 
TERMS OF REFERENCE (April 1981) 
The Scientific Committee for Animal Nutrition is requested to give an 
opinion on the following questions : 
1. Does the use of the coccidiostats Pancoxin (*) and Pancoxin Plus (*) 
in feedingstuffs for chickens and turkeys, under the conditions pro-
visionally authorized (see Background), result in the presence of re-
sidues in animal products ? If so, what is the nature and the amount 
of these residues ? Could these residues be harmful to the consumer ? 
2. Could the use of these additives affect the development of resistance 
in bacteria ? 
3. Could the excreted products derived from these additives be prejudi-
cial to the environment ? If so, what is the nature of the risks ? 
4. In the light of the answers to the above questions, are the condi-
tions of use of these additives acceptable ? 
BACKGROUND 
In accordance with the provisions of Council Directive 70/524/EEC, of 
23 November 1970, concerning Additives in feedingstuffs (1), as last 
amended by the thirty seventh Commission Directive of 9 April 1981 (2), 
(*) Registered trade name 
(1) OJ No L 270, 14.12.1970, p. 1 
(2) OJ No L 131, 18.05.1981, p. 1 
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Member States are authorized by way of derogation to use Pancoxin (*) and 
Pancoxin Plus (*) up to the 30 November 1981 under the following condi-
tions set out in Annex II, Section B, of the Directive : 
: Additive 
: Pancoxin (*) : 
: mixture of 18 parts 
: amprolium (a), 10.8 
: parts sulphaquinoxa-
: line (b) and 0.9 
: parts ethopabate (c) 
: Pancoxin Plus (*) : 
: mixture of 20 parts 
: amprolium (a), 12 
: parts sulphaquinoxa-
: line (b), 1 part 
: ethopabate (c) and 
























Other provisions : 
) Use prohibited : 
) at least seven : 
) days before : 
) slaughter 
OPINION OF THE COMMITTEE 
The Committee noted that the studies on metabolism, residues and excreted 
products from Pancoxin (*) and Pancoxin Plus (*), available in 1981, were 
insufficient and requested that further extensive studies be carried 
out. As supplementary dossiers were now available, the Committee 
expressed the following opinion. 
1. The individual constituents (amprolium, sulphaquinoxaline, ethopabate 
and pyrimethamine) of Pancoxin (*) and Pancoxin Plus (*) have been 
examined toxicologically but not all substances have been studied to 
14 
the same extent. No toxicity or residue data are available on 
chickens and turkeys fed on Pancoxin (*). Metabolism studies are not 
available for pyrimethamine in chickens and for amprolium and ethopa-
bate in turkeys. Residue data are available only for chickens fed on 
amprolium, sulphaquinoxaline and ethopabate or Pancoxin Plus (*) and 
for turkeys fed on sulphaquinoxaline. No information was supplied on 
the nature of the residues for any of the constituent substances. 
Therefore, the Committee considered that the available information 
summarised below is still insufficient to reply fully to question No 
1 put by the Commission. It appeared however that residue data of 
sulphaquinoxaline point to the need for a withdrawal period of at 
least 7 days in chickens and at least 14 days in turkeys. 
1.1. Amprolium 
Metabolism was studied in chicken using orally administered 
14 
C radiolabelled material. Over 90% of radioactivity was 
excreted in 48 hours, about 75% being unchanged amprolium. 
Residues in chicken fed 125-250 mg/kg in the feed for up to 8 
weeks were highest in kidneys but low in liver and muscle. 
After 3 weeks feeding, residues ranged from 1-3 mg/kg in 
kidneys, 0.7-1.7 mg/kg in the liver to 0.2 mg/kg in muscle. 
After 4 days withdrawal, residues were less than 0.01 mg/kg in 
all tissues (limit of detection 0.01-0.02 mg/kg). 
Toxicity studies were performed in mice, rats and dogs. The 
oral LD,__ in mouse and rat was 4 mg/kg b.w. Ninety-day stu-50 
dies in rats and dogs produced weight loss, diarrhoea and in-
creased mortality with the no-effect-level being 200 and 
400 mg/kg b.w. A two year study in the rat was inadequate to 
determine a no-effect-level but showed no carcinogenic effect. 
High doses reduced growth and survival. The two year dog study 
suggests a no-effect-level of 100 mg/kg b.w. No reproduction or 
teratology studies were available. Mutagenicity tests in pro-
karyotic systems were negative. 
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1.2. Sulphaquinoxaline 
Studies of the metabolism in chickens and turkeys showed rapid 
absorption with dose-dependent plasma levels persisting for up 
to 12 hours. Chickens acetylate the compound to a small 
degree. Most species form the insoluble 3-hydroxy derivative 
which is deposited as renal crystals. There is little informa-
tion on metabolites. Sulphaquinoxaline diffuses into eggs in 
proportion to the plasma levels. 
Broilers treated for 2 weeks with a subsequent 7-day withdrawal 
period had residues in the skin of 0.14 mg/kg and in liver, 
kidneys, muscle and fat below 0.1 mg/kg (sensitivity of method 
0.1 mg/kg). Residues in cockerels treated for 2 weeks followed 
by a 7-day withdrawal period were 0.28 mg/kg in kidneys, 
0.1 mg/kg in the liver, 0.11 mg/kg in the skin and less than 
0.1 mg/kg in muscle and fat. Residues in the liver, kidneys, 
muscle and skin of turkeys were below 0.15 mg/kg after 10-14 
days withdrawal periods. Broilers treated for 43 days with Pan-
coxin Plus (*) (60 mg/kg feed sulphaquinoxaline) had no detecta-
ble residues after a 5-day withdrawal period (sensitivity of 
method not stated). 
The toxicity has been studied in several species. The oral 
LDS for mice is 15 g/kg b.w., for rats 1 g/kg b.w. The main 
toxic effects are interference with blood clotting mechanism, 
tubular nephropathy with renal crystal deposition and focal 
hepatic necrosis. A 90-day study in rats showed enlargement of 
the thyroid with a no-adverse effect level of 2 mg/kg b.w., but 
longer studies at high levels produced tubular nephropathy, en-
largement of the thyroid and testicular atrophy. A 90-day study 
in beagle dogs gave similar results with a no-effect-level of 
less than 2 mg/kg b.w. A large number of short-term studies in 
chicken and turkeys produced haemopoietic effects at high doses 
but 120-500 mg/kg b.w. were tolerated over several months. A 
long-term study, multigeneration reproduction study and 
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teratology study in rats showed no abnormal effects at dose 
levels of 0.38-2.5 mg/kg b.w. The mutagenicity studies in pro-
karyotic systems were negative. 
1.3. Ethopabate 
The metabolism was studied in rats, dogs and chicken. Single 
oral doses were almost entirely excreted within 24 hours in the 
urine of all species, almost all as unchanged etho- pabate. 
Chicken excreted 87-100% of oral single doses and 0.07-11% as 
CO , determined by the use of radiolabelled ma- terial. The 
proportion of radioactivity exhaled depended on the position of 
radiolabel. No metabolites or ethopabate were dete- cted in the 
tissues. The metabolite 4-acetylamino-2-ethoxyben- zoic acid 
was identified in the urine of chicken. 
Residue studies in chicken with repeated doses showed the high-
est levels when the aromatic ring was labelled. Levels in the 
kidneys were 1.3 mg/kg, in the liver 0.9 mg/kg and in muscle 
0.2 mg/kg. After 5 days withdrawal residues were 0.05 mg/kg in 
all tissues (sensitivity of method 0.05 mg/kg). If the ethoxy 
group was labelled, residues ranged from 0.05-0.3 mg/kg depen-
ding on dose level and no radioactivity was detectable after 8 
hours in any tissue. If the carboxy group was labelled, resi-
dues were 0.3 mg/kg in muscle, 1 mg/kg in kidneys and 0.6 mg/kg 
in the liver, reducing to 0.05 mg/kg or less after 5 days with-
drawal . 
Toxicity studies include oral LD in mouse and rat (about 
14 g/kg b.w.) and short-term studies in rat, dog and chicken. 
Rat and dog studies with doses ranging from 10 mg/kg to 
5 g/kg b.w. pro- duced mainly hepatotoxicity, the 
no-effect-level for the dog being 10 mg/kg b.w. and for the rat 
100 mg/kg b.w. Feed intake, egg production and hatchability in 
chicken were adversely affec- ted by 500 mg/kg in the feed. 
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Long-term studies in rats and dogs showed only hepatotoxic effe-
cts but no carcinogenic potential. No reproduction or terato-
logy studies were available. Mutagenicity studies in prokaryo-
tes and Saccharomyces were negative. 
1.4. Pyrimethamine 
Metabolic studies in mice, rabbits and monkeys show that 50-60% 
of single oral doses are excreted in the faeces within 24 
hours. Man excretes pyrimethamine slowly, about 12% of the dose 
appearing in the urine within 5 days but excretion is still de-
tectable in the urine for 11 days and in the blood for 7 days. 
The toxicity has been studied in several species. The oral 
LD for mice is 90 mg/kg b.w. Short-term studies extending 
over 42 to 90 days in rats, dogs and monkeys showed the main 
toxic effect to be bone marrow depression together with other 
species specific adverse effects on growth, testes, kidney and 
the gastrointestinal tract. The no-adverse-effect level varied 
from 1.25 mg/kg b.w. in monkeys and dogs to 2.5 mg/kg b.w. in 
rats. Chickens showed similar bone marrow disturbances when 
treated for 56 days with 20 mg/kg b.w. Carcinogenicity studies 
in mice and rats revealed no tumorigenic activity. A multigene-
ration-reproduction study and teratology studies did not suggest 
any adverse reproductive effects. Mutagenicity tests in pro-
karyots bacteria were negative, but genotoxic activity was noted 
in Drosophila and clastogenic activity in bone marrow of mice. 
Of the substances contained in Pancoxin (*) and Pancoxin Plus (*), 
sulphaquinoxaline and pyrimethamine have antibacterial properties. 
Their activity is less than that of sulphamethazol or trimethoprim, 
however. In Pancoxin Plus (*) the two substances show none of the 
synergistic effects which have been described in the case of 
sulphame- thazol and trimethoprim (Guinée 1974, Walter and Heilmeyer 
1975). 
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The effects of sulthaquinoxaline on the percentage of sulphona-
mide-resistant E. coli in the intestinal flora of chickens were stu-
died in vitro and in vivo (Guinée 1974, Guinée and Kruyt 1975). No 
significant difference was observed between treated and untreated 
animals. However, these experiments did not conclusively demonstrate 
that the use of Pancoxin (*) or Pancoxin Plus (*) in animal nutrition 
has no effect on the persistance of E. coli multiresistant to drugs 
since the percentage of these bacteria in the intestinal flora of the 
experimental animals was very high. 
It was found, however, that the resistance to sulphonamides, being 
located on plasmids, would only exceptionally take the form of mono-
resistance in E. coli (Renault 1974, Renault and Decourneau 1975). 
Sulphonamide-resistant E. coli strains show in most cases anything up 
to a five-fold resistance against antibiotics (Renault and Decourneau 
1975, Gedek 1980, 1981, 1982, Siebert 1982, Pohl 1983). The hypo-
thesis that, due to the presence of a quinoxaline cyclic ring, sul-
phaquinoxaline might have antibacterial properties which are diffe-
rent from those of other sulphonamides has not been demonstrated. No 
data are available on the question of whether a loss of R-factors 
may, as in the case of aromatic N-dioxides, result from the admi-
nistration of sulphaquinoxaline. The available data thus do not 
allow a reply to question No 2 put by the Commission. 
Experimental data on the excretion of the individual constituents of 
Pancoxin (*) and Pancoxin Plus (*) are available for chickens only. 
Amprolium and ethopabate are eliminated unmetabolized in droppings; 
sulphaquinoxaline is eliminated for the most part unmetabolized and 
for a small part as an acetyl derivative while pyrimethamine is ex-
creted as a labile acid conjugate. Amprolium is highly hydroso-
luble; sulphaquinoxaline, ethopabate and pyrimethamine are barely 
soluble. The four compounds showed little toxicity for algae, cru-
stácea and fish, as indicated by the data below : 
Chlorella : EC (mg/1, 2 days) : amprolium : 160, pyrime-
thamine : 20 
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Daphnia : EC (mg/l, 2 days) : amprolium : 230, ethopabate : 170, 
sulphaquinoxaline : | 7.5, pyrimethamine : 4.8 
Lebistes : EC (mg/l, 2 dyas) : amprolium : 270. LC (mg/l, 2 
days) : ethopabate : 105, sulphaquinoxaline : | 7.5, pyrime-
thamine : 7.5 
Salmo gairdneri : LC (mg/l, 2 days) : amprolium : 1550, etho-
pabate : 23, sulphaquinoxaline : | 7.5, pyrimethamine : 5.9. 
The phytotoxic potential of Pancoxin Plus (*) has been tested on 
eight plant species at concentrations between 1 and 1.000 mg/kg 
soil. No phytotoxicity was observed for lettuce, beans, peas and 
sunflower. A 50% reduction in plant growth was observed at high con-
centrations (between 285 and 1067 mg/kg soil) on oats, rape, tomatoes 
and maize. 
In vitro studies showed that Pancoxin (*) as well as Pancoxin 
Plus (*) do not substantially affect methanogenesis and reduce nitri-
fication only at concentrations distinctly in excess of those that 
can be attained in soil after spreading of slurry. 
The results currently available, although incomplete, suggest that 
these substances do not constitute a significant environmental risk. 
4. In view of the foregoing, the Committee considers that it is unable 
to issue an opinion on the use of Pancoxin (*) and Pancoxin Plus (*) 
in feedingstuffs for chickens and turkeys before the following addi-
tional data are available : 
a) reproduction and teratology studies on amprolium and ethopabate; 
b) in vivo mutagenic studies (chromosomal effects) of amprolium, 
sulphaquinoxaline and ethopabate; 
c) metabolism and tissue residues of pyrimethamine in chicken; 
d) metabolism and tissue residues of amprolium and ethopabate in 
turkey; 
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e) data showing that the metabolism and residues of individual com­
ponents are not affected when the mixture Pancoxin (*) or Pancoxin 
Plus (*) is used; 
f) effects of Pancoxin (*) and Pancoxin Plus (*) on the persistance 
of E. coli multiresistant to drugs in the alimentary tract of 
treated animals; 
g) kinetics and degradation of amprolium, sulphaquinoxaline, ethopa­
bate and pyrimethamine in soil and water. 
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SECOND REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF LERBEK (*) IN FEEDINGSTUFFS FOR TURKEYS 
Opinion expressed 11 July 1984 
TERMS OF REFERENCE (July 1978 expanded in October 1981) 
In reply to questions put by the Commission on the use of Lerbek (*) 
(premix containing 100 parts of meticlorpindol and 8.35 parts of methyl-
benzoquate) in feedingstuffs for turkeys, the Committee, in its report of 
17 November 1981 (**), delayed expressing its opinion until data on meta-
bolism of Lerbek (*) in turkeys, its residues and excreted products be-
came available. Since the appropriate studies have now been carried out 
the Committee expressed the following opinion. 
OPINION OF THE COMMITTEE 
1. Residues of meticlorpindol (MCP) in tissues and excreta have been 
studied in two groups of turkeys. In the first one, the birds were 
given a daily dietary administration of MCP (100 mg/kg feed) for 14 
14 days followed by a single oral dose of C-MCP (6.5 mg/kg feed). 
The MCP (3,5-dichloro-2,6-dimethyl-4-pyridinol) was ring labelled in 
positions 2 and 6. The birds were then slaughtered after 24 h, 48 h 
or 72 h. To the second group, Lerbek (*) was given for 14 days 
14 followed by a single oral dose of C-MCP (6.5 mg/kg feed) and un-
labelled methylbenzoquate (MBQ) (0.54 mg/kg feed). In both treatment 
groups a mean value of about 90% of the radioactivity administered 
was collected in the combined excreta during a 72 hour period follo-
wing dosage with the labelled MCP. Approximately half was present as 
unchanged MCP, the remainder being non identified. 
(*) Registered trade name 
(**) Reports of the Scientific Committee for Animal Nutrition, fourth 
series (1984), No EUR 8769, p. 87 
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The level of radioactivity in tissues, expressed as ug equivalents 
14 
C- MCP/g, ranged, after 72 h, from 0.3 to 1.1 in liver and 
kidneys, and 0.1 to 0.4 in muscle. Unchanged MCP accounted for 
59-82% of the radioactivity. The similarity of the results obtained 
with both treatments showed that MCP metabolism is not changed in 
presence of MBQ. 
In turkeys given Lerbek (*) at the proposed level (110 mg/kg feed) 
for a period of 12 weeks and then sacrified at various times there-
after, no residues of MBQ were detected (limit of detection : 
0.02 mg/kg) in muscle, liver and kidney after a 24 hour-withdrawal 
period and no residues of MCP were detected (limit of detection : 
0.05 mg/kg) after a 7 day-withdrawal period. 
From the foregoing it appears that the use of Lerbek (*) in feeding-
stuffs for turkeys gives comparable residues in tissues to those re-
sulting from its use in chickens. 
2. Also from the foregoing and the relevant data given in the report on 
the use of lerbek (*) in feedingstuffs for chickens (**), it appears 
that this product can be used in feedingstuffs for turkeys without 
risks for the consumer or the environment. 
3. In the light of these findings, the Committee is of the opinion that 
the conditions proposed for the use of Lerbek (*) in feedingstuffs 
for turkeys (110 mg/kg complete feedingstuffs and a withdrawal period 
of at least 5 days before slaughter) are acceptable. 
REFERENCES 
Dossiers Dow Chemical and HRC (1984) 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON THE USE 
OF ZINC BACITRACIN IN FEEDINGSTUFFS FOR POULTRY. PIGS AND RABBITS 
Opinion expressed 30 January 1985 
TERMS OF REFERENCE (September 1980) 
The Scientific Committee for Animal Nutrition is requested to give its 
opinion on the following questions : 
1. Does the addition of zinc bacitracin to complete feedingstuffs in 
dose levels higher than 20 mg/kg produce a significant increase of 
nutritional effects, free of prophylactic or therapeutic effects, in 
the case of poultry (excluding turkeys, ducks, geese, laying hens and 
pigeons) over the age of four weeks, swine over the age of four 
months, and rabbits ? 
If so, what is the dose/response ratio ? 
2. Is the administration of complete feedingstuffs with a maximum zinc 
bacitracin content of 100 mg/kg justified from a nutritional point of 
view 
- in the feeding of poultry (excluding turkeys, ducks, geese, laying 
hens and pigeons) up to the age of 16 weeks, 
- in the feeding of swine up to the age of six months, 
- in the feeding of rabbits ? 
3. Does the use of zinc bacitracin in feedingstuffs for poultry, pigs 
and rabbits, under the conditions of use being proposed (cf. Back-
ground) , result in the presence of residues in animal products ? 
If so, what is the nature and the amount of these residues ? Could 
they be harmful to consumers ? 
4. Could these conditions of use lead to the development of resistance 
in bacteria ? 
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5. Could they be harmful to the environment ? 
If so, what is the nature of the risks ? 
6. In the light of the answers to the above questions, are the condi-
tions of use being proposed acceptable ? 
BACKGROUND 
In accordance with Council Directive 70/524/EEC of 23 November 1970 con-
cerning additives in feedingstuffs (1), as last amended by the 34th 
Commission Directive of 4 September 1980 (2), the use of zinc bacitracin 
is authorized throughout the Community, subject to the conditions of use 
set out as follows in Part A of Annex I to the Directive : 
: Species of animal 
: Turkeys 
: Poultry, excluding turkeys, ducks, 
: geese, laying hens and pigeons 
: Laying hens 
: Calves, lambs and kids 
: Piglets 
: Swine 
: Animals bred for fur 
: Maximum age 
: 4 weeks, 
: from 4 to 
: 26 weeks 
4 weeks, 




from 16 weeks 




from 4 to 
6 months : 
_ ; 
: Minimum : Maximum : 
: content : content : 
: ppm (mg/kg) of 














: 50 : 
: 20 : 










(*) Milk replacers 
(1) OJ No L 270, 14.12.1970, p. 1 
(2) OJ No L 251, 24.09.1980, p. 17 
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The proposed amendments to these conditions of use are given in the table 
below : 
: Species of animal 
: Turkeys : no change 
: Poultry, excluding turkeys, ducks, 
: geese, laying hens and pigeons 
: Laying hens : no change 
: Calves, lambs, kids : no change 






Minimum : Maximum : 
content : content : 









In the opinion delivered on 21 February 1978 (3), the Scientific 
Committee for Animal Nutrition reserved its position regarding any in-
crease in the dose levels authorized for zinc bacitracin, given the lack 
of supporting data. As further relevant material is now available, the 
Commission considers that the matter should be re-examined. 
OPINION OF THE COMMITTEE 
The dossiers made available to the Committee were those on zinc 
bacitracin produced by A/S Apothekernes Laboratorium for Special-
praeparater. 
(3) Reports of the Scientific Committee for Animal Nutrition, First 
Series (1979). Office for Official Publications of the European 
Communities, Luxembourg. Catalogue No CB-28-79-277-FR-C. 
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Considering that the data available up to 1982 did not enable a sa-
tisfactory assessment to be made of the effects of an increase in the 
dose levels of this antibiotic, the Committee requested that additional 
studies be carried out on the efficacy of the product, the matabolism and 
residues, mutagenicity, bacterial resistance and the effects on the en-
vironment. The results of these studies were submitted during 1984. The 
opinion delivered hereinafter is none the less restricted to broilers and 
pigs, the only target species to have been the subject of appropriate 
studies under the newly proposed conditions of use. 
1. and 2. The nutritional effects of zinc bacitracin were established on 
the basis of 839 tests involving 178 000 broilers and 207 tests 
ivolving 6 400 pigs. The parameters considered were the in-
crease in liveweight gain and the improvement in the feed con-
version ratio among the groups given feed containing zinc baci-
tracin as compared with the control groups. The zinc baci-
tracin content of the additive-containing feeds varied between 
3 and 275 mg/kg for the fowl and between 3 and 250 mg/kg for 
the pigs. 
Processing the results by multiple regression analysis enabled 
a statistically significant dose/response ratio to be worked 
out for each parameter and allowed the optimum concentrations 
of the additive to be assessed for broilers and pigs (Morris 
1983). On account of the high number of variables associated 
with the trials (breed, ration composition, breeding condi-
tions, etc.), the parameters included in the multiple 
regression equation enable the variance to be explained in part 
only (21 to 32%). 
For broilers, the optimum zinc bacitracin concentration is 
110 mg/kg of feed for the increase in liveweight gain and 
130 mg/kg of feed for the improvement in the feed conversion 
ratio. For pigs, the optimum concentration is 106 mg/kg of 
feed for the increase in liveweight gain and 125 mg/kg of feed 
for the improvement in the feed conversion ratio. 
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For both species, the favourable effects of the additive up to opti­
mum concentration show a gradual reduction with the increase in con­
centration. 
Although the yield is not proportional to the dosage used, the in­
crease in the concentration of zinc bacitracin in feedingstuffs for 
broilers and pigs up to 100 mg/kg feedingstuff is justified by sta­
tistically significant nutritional effects. Since these studies were 
performed on healthy animals, the likelihood of prophylactic or spe­
cific therapeutic effects can be ruled out. 
Bacitracin is a polypeptide antibiotic produced by Bacillus licheni-
formis; its main components are the dodecapeptides, bacitracins A, 
Β , Β and F . The acute toxicity of bacitracin has been de­
termined in the mouse, rat, rabbit and dog by various routes of ad­
ministration. The subacute toxicity has also been tested in the 
mouse, rat, rabbit, dog and monkey by various routes, including a 
subchronic oral feeding test in rats extending over 90 to 365 days. 
No toxic effects were noted. Furthermore, bacitracin did not irri­
tate skin or eyes. 
Zinc bacitracin was tested for mutagenicity in the Salmonella reverse 
mutation test, in a mouse lymphoma gene mutation test, an in vitro 
test for chromosomal aberrations in human peripheral lymphocytes and 
in rat bone marrow cells. No mutagenic activity was detected. DNA 
metabolism in spleen cells in vitro showed also no adverse effects. 
Thus bacitracin lacks mutagenic activity and there is therefore no 
reason to suspect genotoxic carcinogenic activity. 
Bacitracin is appreciably resistant to hydrolysis by mammalian pro­
teases and peptidases due to its cycloheptapeptide substructure, its 
thiazoline ring in the N-terminal L-isoleucine-L-cysteine moiety and 
to the presence of four D-amino acids (D-glutamine, AA 4, D-orni-
thine, AA 7, D-phenylalanine, AA 9, D-aspartic acid, AA 11). Only 
some 4% of ingested bacitracin is broken down to di- and tripeptides 
and free amino acids. 
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Zinc bacitracin metabolism has been studied in rats, chickens and 
piglets using single oral doses of the antibiotic labelled with 
14 
C-L-isoleucme in AA positions 1, i> and 8 in the molecule. The 
doses administered were 80 mg/kg live weight for the rat, 20 mg/kg 
live weight for the chicken and 7 mg/kg live weight for the piglet; 
with the piglets dosing with the labelled product was preceded by the 
administration of a ratio containing 117 mg zinc bacitracin/kg feed 
for 18 days. Of the administered dosages, 102% was recovered in rat 
faeces and 96% in piglet faeces; vfith the chicken 95% of the admi­
nistered dose was recovered in the combined excreta (faeces and 
urine). Analysis by TLC/autoradiography of the rat and piglet faeces 
and the chicken excreta showed the presence of oxidised derivatives 
(i.e. bacitracins F) of: the bacitracins Α, Β and Β , of desami-
dobacitracins and di- and tripeptides in addition to the original 
bacitracin supplied in the feed. Rat and piglet urine contained res­
pectively 3.2 and 3.67<> of the administered dose while the comparable 
values for bile were 0.5% and 0.03% respectively. No bacitracins or 
their near derivatives were detected in the bile or urine, nor was 14 there any C-labelled free isoleucine. 
Traces of radioactivity were found in some samples of liver and 
kidney from the chick (limit of determination 0.027 mg/kg fresh 
weight) and in liver, kidney, lung and heart of the piglet (limit of 
determination 0.0038 mg/kg fresh weight). The negligible quantities 
of these tissue residues, which persisted for some 5-7 days in some 
animals after withdrawal of the antibiotic from the feed, were not 
identified. Howeiver, extracts of the liver failed to show any micro­
biological activity. Tissues from chicken and piglets kept on feeds 
containing 100 mi» or more zinc bacitracin for periods up to one month 
or more contained no bacitracin detectable by microbiological assay 
(limit of determination 0.054-0.26 mg/kg). Therefore, no harm to the 
consumer arises. 
4. The administration of zinc bacitracin in various concentrations up to 
100 mg/kg feedingstuff to pigs and broilers only slightly altered the 
number of bacteria in the intestinal flora as far as the main species 
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were concerned, i.e. lactobacilli, enterococci, E. coli and staphy­
lococci (Gedek, 1983; Walton, 1983). 
The slight increase in the MIC values observed mainly in the ente­
rocci vis­à­vis bacitracin used as a feed additive was not accompa­
nied by reduced sensitivity to other antibiotics used therapeutically 
(inter alia ß­lactam antibiotics, tetracyclines and chloramphe­
nicol). Furthermore, after administration of zinc bacitracin to pigs 
and chickens for several weeks, a lowering of the resistance of en­
terococci and E. coli in the intestinal flora of these animals to se­
veral drugs (antibiotics, sulphonamides, nitrofurans, etc.) used in 
human and veterinary medicine was noted. The concentration of 
100 mg/kg of feed led to a greater reduction that did 20 mg/kg 
(Walton 1978, 1983; Walton and Laerdal 1980; Siebert, 1982). 
After administration of zinc bacitracin, the products excreted by pig 
and chicken were made up of bacitracin A, Β and F, desamidobaci­
tracins, breakdown products and non­extractable components bound to 
faeces constituents. Their antibiotic activity fell sharply in ex­
creta and soils. The half­life of zinc bacitracin mixed with the ex­
creta of chicken is two to seven days depending on the temperature. 
This rapid loss of antibacterial activity due to oxidative deamina­
tion means that any effect on the nitrifying bacteria in the soil may 
be ruled out. Nitrogen­fixing bacteria (Rhizobium trifolii) are not 
sensitive to zinc bacitracin, even in high concentrations. Under ex­
perimental conditions, bacitracin inhibits the formation of methane 
in sludges even in a 3 mg/kg concentration (Hilpert et al., 1983). 
On account of its rapid inactivation in excreta however, it does not 
seem that in practice, zinc bacitracin could affect the production of 
biogas. 
Bacitracin does not present any risk to fish, shellfish or algae. No 
adverse effect was observed on trout (Salmo gairdneri) fed for 110 
days on feed containing 57.5 and 104 mg zinc bacitracin/kg respecti­
vely. The CL after 96 hours for this species is 74 mg/1. 
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For Daphnia magna, the minimum concentration without any effect is 
3.2 to 5.6 mg/1, and the CL after 48 hours is 34 mg/1. The 
growth of green algae (Chlorella ellipsoides) is not affected by zinc 
bacitracin at a concentration of 10 mg/1. 
No inhibiting effect on the growth of plants was observed in plant 
species grown in soils mixed with manure from poultry fed with feed 
containing from 20 to 100 mg zinc bacitracin/kg or poultry manure 
mixed with 150 mg zinc bacitracin/kg. 
On the basis of the foregoing information, the Committee is of the 
opinion that the use of zinc bacitracin levels of 5-100 mg/kg com-
plete feedingstuffs for broilers up to the age of 16 weeks and pigs 
up to the age of six months is justified for the animal production 
and does not present any risk for human or animal health or for the 
environment. 
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SECOND REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF N1CARBAZIN IN FEEDINGSTUFFS FOR FATTENING CHICKEN 
Opinion expressed 5 July 1985 
In accordance with its opinion delivered on 14 April 1982 (*) and having 
received from the firm Merck, Sharp and Dohme further documentary infor-
mation on nicarbazin, the Committee reassessed the use of the additive in 
feedingstuffs for fattening chicken. For the purposes of reassessment, · 
all the data on nicarbazin supplied up to June 1985 were taken into con-
sideration. 
Further studies on residues in the tissues of chicken (liver, kidney, 
muscles, skin, fatty tissues) carried out in 1983 and using an improved 
Polarographie method to determine the levels of DNC (limit of determina-
tion expressed in terms of nicarbazin : 0.1 mg/kg) have shown that the 
actual values are higher than those previously estimated by extrapolation 
from results obtained using a low-sensitivity Polarographie method. No 
data have been made available as to the metabolism of nicarbazin in 
chicken. 
Additional studies carried out in 1983 and 1985 on the environmental 
effects of nicarbazin have shown that nicarbazin is not phytotoxic and 
has no significant effects on aquatic life, methanogenesis or bacterial 
nitrification. No data have been made available on the biodegradability 
in dung and soil of excreted products derived from nicarbazin. 
While taking account of the additional information on tissue residues, 
the Committee considers that, in the absence of data on the metabolism of 
nicarbazin and the qualitative composition of its residues, the with-
drawal period for the supplemented feedingstuff before slaughter should 
be extended to 9 days, at least so that the residue levels estimated by 
determination of DNC do not exceed 0.2 mg/kg. 
(*) Reports of the Scientific Committee for Animal Nutrition, fourth 
series (1984), No EUR 8769, p. 51 
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However, the Committee is unable to deliver a final opinion as to whether 
the use of nicarbazin is harmless until appropriate studies have been 
carried out on the metabolism of the product in chicken and the 
biodegradation of its excreted products in dung and soil. 
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REPORT ESTABLISHED JOINTLY BY THE SCIENTIFIC COMMITTEE FOR ANIMAL 
NUTRITION AND THE SCIENTIFIC COMMITTEE FOR FOOD ON THE USE IN 
ANIMAL NUTRITION OF PROTEIN PRODUCTS OBTAINED FROM CANDIDA YEASTS 
Opinion expressed 3 May 1984 
TERMS OF REFERENCE (January 1983) 
The Scientific Committee for Animal Nutrition and the Scientific 
Committee for Food are requested to give their opinion on the following 
questions : 
1. Do the products obtained from yeasts of the Candida variety and, in 
particular, from those cultivated on n-alkanes have a nutritional 
value for animals because they provide nitrogen or protein ? 
2. Can the use in animal nutrition of products obtained from yeasts of 
the Candida variety and, in particular, from those cultivated on 
n-alkanes result in risks for human (consumer or user) or animal 
health, or be prejudicial to the environment ? 
BACKGROUND 
In accordance with the provisions of Council Directive 82/471/EEC of 
30 June 1982 concerning certain products used in animal nutrition (0), 
Member States may, until such time as a Community decision has been 
taken, maintain authorizations granted within their territories before 
notification of the Directive concerning on the one hand products ob-
tained from yeasts of the Candida variety and cultivated on n-alkanes and 
on the other hand products listed in Section 1.2.1. of the Annex to the 
Directive (yeasts cultivated on substrates of animal or vegetable origin) 
meeting requirements different from those laid down therein. 
(0) OJ No L 213, 21.07.1982, p. 8. 
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In accordance with the established procedure, the Commission consults the 
Scientific Committee for Animal Nutrition and the Scientific Committee 
for Food before producing a draft of the Community measures to be adopted 
for the compounds concerned. 
OPINION OF THE COMMITTEES 
The Committees draw the attention of the Commission to the fact that 
yeasts of the Candida variety are not a homogeneous group of micro-
organisms in relation to their nutritional value and their pathogenicity 
(difference in virulence) for man and animals. 
The Committees have made some general comments on the nutritional and 
pathogenicity aspects of Candida yeasts. In the absence of other rele-
vant documentation they have evaluated the safety of only two specific 
products derived from two strains of Candida on which information has 
been provided, namely Toprina (*) and Liquipron (*). 
Toprina (*) and Liquipron (*) are trade-marks for dried whole yeasts 
obtained by growing Candida lipolytica strain 246 and Candida strain ATCC 
20275 IS respectively on n-alkanes containing culture media. The term 
Candida tropicalis is used in the text. However, there is no complete 
agreement on the actual classification of the Candida strain used as the 
source material for Liquipron (*). 
1. Nutritional aspects 
Candida yeasts may be broken down into groups according to the 
various substrates on which they can be grown, as indicated in the 
table below. 














C. boidinii (1) 
Effluents and 
cellodextrins 
C. pelliculosa (13) 
C. wickerhamii (a) 
for the production of methanol 
also grown on sulphite solution (12), molasses and 
by-products 
Whey : 
C. fabrianii (10): 
C. frigida (11) : 
C. krusei (20) : 
other sugar : 
Extensive literature on the nutritional value of their proteins is 
available for C. lipolytica and C. tropicalis strains cultivated on 
n-alkanes. The crude protein content (Ν χ 6.25) of products obtained 
from these micro-organisms varies from 60% to more than 70% on the 
basis of dry matter. Their protein efficiency (ratio between animal 
weight gain and quantity of proteins ingested) has been determined in 
various animal species (2, 3, 4, 5, 6, 8, 9, 19). In the rat, this 
efficiency is around 2.2-2.5 when the ration has been supplemented 
with 0.3% DL-methionine. 
Except for low methionine levels, the amino-acid composition of 
C. lipolytica and C. tropicalis proteins is close to that of the 
egg. Lysine and threonine, limiting factors of the usual pig and 
poultry rations, are supplied in large measures by proteins obtained 
from Candida strains. At levels of 15% in the ration, these products 
cover 88% of chickens' and more than 100% of piglets' lysine require­
ments . 
Studies on rats have shown that, at incorporation rates higher than 
15% in the ration, the protein efficiency of products from C. lipoly­
tica drops as the concentration increases in the same way as that of 
casein and whole egg which has been freeze-dried and heated at 60°C 
(7). 
Provided nutritional balance is maintained, products from C. lipoly­
tica and C. tropicalis strains can be used at levels up to 15% 
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in the rations of pigs, calves, lambs, poultry, pets, with the ex-
ception of the Dalmatian dog whose ration should not contain more 
than 3-4% of these yeasts (18). On the other hand, fish can be given 
high levels of them in their ration (14, 15, 16, 17). On account of 
their content in nitrogen compounds with high biological value, these 
products have a nutritional value comparable to or even higher than 
that of other sources of proteins commonly used in animal feed. 
2. Risk assessment 
2.1. Pathogenicity and hypersensitivity 
2.1.1. General considerations on Candida strains 
Viable Candida yeasts are so-called opportunistic pathogens, 
i.e. they may induce in predisposed hosts (human or animal 
organism) various forms of mycoses. Depending on exposure 
conditions, specific virulence of the strain and host factors, 
these mycoses may range from mild superficial infections to 
deep organ invasions (with predilection for kidney and brain) 
and generalized septicaemia which, if untreated, rapidly 
causes death (1, 6, 7). The skin, oral cavity and urogenital 
tract are more commonly affected in human beings, whereas the 
digestive tract is usually involved in young livestock (7, 
8). Sometimes, a mycoallergy develops in addition to the 
underlying mycoses (7, 9). Both an overt and a latent in-
fection during pregnancy may have serious consequences if via-
ble cells of an opportunistic Candida strain are transmitted 
to the newborn at delivery. 
Over the past ten years infections caused by Candida species 
have increased noticeably in number, severity and spectrum of 
causative species (14). This increase is reasonably attribu-
ted to the increase in predisposing factors which are 
generally a prerequisite for an organism being affected by a 
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candidosis. A severe form of candidosis may also occur in a 
healthy host when a high number of viable cells of the most 
virulent strains is administered. In humans, the predisposing 
factors include several metabolic disorders (e.g. diabetes), 
underlying bacterial or viral infections, treatment with 
broad- spectrum antibiotics, lowered resistance due to 
exposure to immunosuppressants (cytostatics or corti-
costeroids) , congenital myelodeficiency and malignant disease 
(8, 14). 
Candida-induced mycoses very often occur in animals in 
connection with the use of chemotherapeutics which, in warm-
blooded animals, favour the development of yeasts by suppres-
sing the normal intestinal flora (6). The use of medicated 
feedingstuffs may also result in an increased excretion of 
viable Candida yeast cells (5). Recently Candida yeasts have 
been shown to induce diseases also in freshwater fish (4). 
Not all species of Candida are endowed with pathogenic proper-
ties for human or animal organisms (1, 6, 12, 14, 17, 16); 
this only happens when the optimal growth of the yeast occurs 
at the host body temperature and the yeast is able to with-
stand the various defence mechanisms that the host puts into 
play (among which phagocytosis is of utmost importance). The 
formation of mycelia or pseudomycelia is widely held to 
account for increased resistance of Candida to phagocytosis 
and for virulence in general (14), but other factors may con-
tribute to the invasive properties of the micro-organism, 
particularly enzymes (mainly proteases) and cell glycoproteins 
(endotoxin-like substances) (7, 10, 16, 3). 
A review of the current literature, covering both experimental 
and clinical reports, clearly shows that the following eight 
species of Candida are true pathogens (in this context "pa-
thogenic" means "capable of inducing harmful effects in a 
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compromised host" with the understanding that the virulence 
will depend on the particular strain) : C. albicans; C. tro-
picalis; C. stellatoidea; C. glabrata; C. parapsilosis; 
C. pseudotropicalis; C. guilliermondii; C. krusei. According 
to Odds (14), all the traditional Koch's postulates, which 
still remain the orthodox criteria for judging a species to be 
regarded as pathogenic, are satisfied for these eight Candida 
species. 
Moreover, the following Candida species have been occasionally 
isolated from human or animal tissues: C. claussenii; 
C. intermedia; C. brumptii; C. lipolytica; C. solani; 
C. ravantii; C. pulcherrima; C. ingens ; C. lambica; C. mace-
doniensis and C. norvegensis. For these Candida species a 
strong aetiological association with a disease has not been 
documented but is, however, suspected. Lastly, C. viswanathii 
has been shown recently to be highly pathogenic in the mouse 
(2). C. ingens has been reported as a cause of septicaemia in 
surgical patients (15) and strains of C. utilis have been 
described which are virulent for the mouse and possess very 
active cytoplasmic toxins (10). 
It must be stressed here that the information reported above 
about the pathogenicity of Candida organisms is derived either 
from clinical evidence in men and/or animals or from experi-
mental infections in laboratory animals. There is a great 
lack of knowledge about the consequences of animal or human 
exposure to a "high" number of viable yeast cells or to repea-
ted exposure to these cells. There is no doubt, however, that 
the continuous inhalation and/or ingestion of huge amount of 
viable yeast will affect the host immune system and may give 
raise to serious hypersensitivity reactions considering the 
strongly antigenic nature of the Candida cell surface. 
Based on the above evidence, it may be concluded that the use 
of some Candida yeast strains for manufacturing single cell 
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proteins as animal feeds may pose serious risks not only to 
(i) workers (if exposed to viable yeast cells in production 
plants or during preparation and/or administration of feeds) 
and (ii) population groups (if exposed to emissions of viable 
yeast cells from manufacturing plants), but also to (iii) con-
sumers of animal products containing viable yeast cells, (iv) 
farm animals exposed to viable yeast cells through contamina-
tion of the environment. Therefore, particular strains of 
Candida yeasts should not be permitted for industrial use in 
SCP manufacturing unless sufficient data are available to show 
that the strain employed is non-pathogenic and/or does not 
elicit serious hypersensitivity reactions. 
2.1.2. Specific considerations relating to Candida strains used for 
manufacturing Toprina (*) and Liquipron (*) 
Ç_. lipolytica, strain No 246, and Candida sp., strain No ATCC 
20.275 is cultivated on n-alkanes for manufacturing Toprina 
(*) and Liquipron (*) have been tested for pathogenicity in 
several laboratory animal species. The results obtained 
showed that the two strains did not proliferate but exhibited 
a tendency to persist especially in the kidneys of infected 
animals. This behaviour was, however, not significantly 
different from that of non-pathogenic C. utilis strains chosen 
as reference organisms. No data are available on the effects 
of the ingestion of Toprina (*) and Liquipron (*) on micro-
organisms of the flora of the alimentary tract and on the 
colonization of pathogens in the alimentary tract. 
Consequently, to protect consumers of animal products, workers 
involved in the preparation and administration of 
SCP-containing feeds, farm animals fed SCPs and the 
environmental organisms that might be exposed through 
contamination of the environment from mycoses and 
mycoallergies, Toprina (*) and Liquipron (*) should not be 
- 41 -
permitted as animal feeds unless, in addition to the qualifi­
cation of non-pathogenicity referred to in the previous 
section, they are also proven to be free of viable cells by a 
sensitive recognised method, the limit of detection of which 
is defined. 
2.2. Biological and toxicological aspects 
The biological effects of incorporating Toprina(*) or 
Liquipron(*) in the ration have been examined in a number of 
target species. The lipids of these products and probably of 
other Candida products from yeasts grown on n-alkanes contain 
a much higher percentage of odd-carbon-atom-number fatty 
acids, mainly C , than the usual dietary lipids. Investi­
gations of the effect of the presence of these fatty acids in 
Toprina (*) and Liquipron (*) showed a dose-dependant 
accumulation of these fatty acids in the lipid fraction of all 
tissues as well as in milk and eggs in target species. 
Accumulation was greatest in the adipose tissue and involved 
mainly C and C fatty acids. Young poultry accumulated 
these fatty acids faster than older birds, while eggs accumu­
lated more than body tissues. Similar accumulation was 
detected in the adipose tissue of mice, rats and monkey. 
These fatty acids were also present in the lipid fraction of 
brain, heart, liver and blood platelets. Accumulation usually 
reached a plateau after about 2 months feeding indicating 
steady state kinetics (1, 5, 29, 25). 
Residues of n-alkanes ranging from 0.1 to 0.4% were detected 
in several samples of Toprina (*) and Liquipron (*) (9, 30). 
Investigations carried out on many target species have shown 
that η-alkane residues were also present in the adipose tissue 
and muscle of animals fed yeasts grown on η-alkane sub­
strates. Accumulation levels reached a plateau usually within 
two months of continuous feeding of these yeasts in the ration 
(1, 6, 18, 26). 
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Subchronic feeding studies in rats, using levels up to 30% 
Toprina (*) or 20% Liquipron (*) in the diet showed no adverse 
findings (8). These studies included two 90-day studies with 
Toprina (*) and an 11 months study with Liquipron (*). 
Lifespan studies were also carried out with both products. 
Two rat studies extending over 104 weeks and a mouse study 
lasting over 78 weeks were performed with Toprina (*) given at 
levels up to 30% in the diet. Apart from minor organ weight 
changes in rats, confined either to one sex or not dose-
related, no carcinogenic or other adverse effects were noted 
in either species. Growth was somewhat reduced in all mice on 
yeast diet (17, 20, 22, 27). 
A lifespan study in rats extending over 30 months with dietary 
levels of Liquipron (*) up to 26% showed an increased 
incidence of lymphomas in females and less so in the males. 
The rise in tumour incidence in females appeared to be related 
to dose (13). However, in the absence of knowledge of the 
incidence of these tumours in historical controls and with no 
mutagenicity data available, it is not possible to interpret 
these findings. These may well be due to epigenetic mecha-
nisms. A second study, extending over 17 months, at a dietary 
level of 20% produced kidney calcification as the only adverse 
finding (23). A 28 months study in mice at a dietary level of 
30% produced calcification in the hearts and kidneys of males 
and the kidneys of females. The only adverse finding in a two 
year dog study with Liquipron (*) was a dose-related reduction 
in body weight gain. Monkeys fed 2% Liquipron (*) for 2 years 
showed no adverse effects apart from diarrhoea and soft stools 
(24). 
Reproductive and teratological studies with up to 30% of 
Toprina (*) in rats showed no adverse effects due to treatment 
(9, 21, 28a). Similar studies in mice with up to 27% 
Liquipron (*) produced only slight growth depression at the 
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highest test level. In rats the same top dose showed some 
adverse effects on pre- and post-implantation as well as on 
litter parameters. Maternal behaviour towards the litter also 
showed a dose-related adverse change. Some delayed ossifica-
tion was also noted. Embryotoxicity was also noted when 17% 
Liquipron (*) was administered to pregnant rabbits (14, 15, 
12). 
The only existing mutagenicity test is a dominant lethality 
assay with Toprina (*), which was negative (28b). Liquipron 
(*) has not been tested for mutagenicity. The relay toxicity 
studies on Toprina (*) and Liquipron (*) did not yield any 
meaningful results (11). 
A series of special studies was carried out on pregnant rats 
using the lipid fraction extracted from Toprina (*) at a 
dietary level equivalent to 75% Toprina in the diet. Examina-
tion of the progeny revealed some disturbance in the early 
myelination pattern in the brain and delayed maturation in 
post natal development (7). Similar effects were also 
produced by feeding the corresponding odd-carbon-atom-number 
fatty acids. These fatty acids were found in the lipids of 
treated rats, the milk and the progeny, this being evidence of 
passage accross the placenta (2, 3). Tissue microsomes 
associated with cytochrome b_ and cytochrome b_ reductase 
b 5 
induction also contained these fatty acids but the mito-
chondria were normal. In contrast rats treated with up to 16% 
Liquipron (*) for 3 months and longer showed no effects on 
hepatic microsomal enzymes, haematological parameters, motor 
activity, coordination and neurotransmission except for slight 
increases in acetycholine and 5-OH-indoleacetic acid, slight 




In the light of these data the Committees did not consider it feasi­
ble to assess the risks for the consumer of the use of protein 
products obtained from Candida yeasts cultivated on n­alkanes. The 
interpretation of some of the experimental findings was rendered 
difficult by the lack of certain basic data. In particular, informa­
. tion is missing on : 
(a) the mutagenic activity of the relevant fractions of both Toprina 
(*) and Liquipron (*) biomass in in vitro systems, with and 
without metabolic activation, and in in vivo systems, 
(b) the dose levels of lipids, extracted from these yeast products, 
which on ingestion do not produce any neurobehavioural and/or 
neuropathological changes in the progeny of treated laboratory 
animals, 
(c) the dose levels of lipids extracted from the milk and eggs of 
animals ingesting these yeast products in their feed, which do 
not result in neuropathological and neurobehavioural changes in 
the progeny of treated laboratory animals, 
(d) and the classical toxicological effects of fatty acids containing 
linear chains of 15 or 17 carbon atoms. 
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REPORT ESTABLISHED JOINTLY BY THE SCIENTIFIC COMMITTEE FOR ANIMAL 
NUTRITION AND THE SCIENTIFIC COMMITTEE FOR FOOD ON THE USE IN 
ANIMAL NUTRITION OF PROTEIN PRODUCTS OBTAINED FROM BACTERIA 
OF THE METHYLOMONADACEAE FAMILY 
Opinion expressed 25 September 1985 
TERMS OF REFERENCE (October 1983) 
The Scientific Committee for Animal Nutrition and the Scientific 
Committee for Food are requested to give their opinion on the following 
questions : 
1. Do the products obtained from bacteria of the family of Methylomona-
daceae and, in particular, from Methylophilus methylotrophus cultiva-
ted on methanol (Pruteen) (*) have a nutritional value for animals 
because they provide nitrogen or protein ? 
2. Can the use in animal nutrition of products obtained from these 
bacteria and, in particular, from Pruteen (*) result in risks for 
human (consumer or user) or animal health, or be prejudicial to the 
environment ? 
BACKGROUND 
In accordance with the provisions of Council Directive 82/471/EEC of 
30 June 1982 concerning certain products used in animal nutrition (**), 
Member States may, until such time as a Community decision has been 
taken, maintain authorizations granted within their territories before 
the date of application of the Directive concerning in particular 
products not listed under the product group indicated in Section 1.1. 
(Bacteria) of the Annex to the Directive. 
(*) Registered trade name. 
(**) OJ No L 213, 21.07.1982, p. 8 
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In accordance with the established procedure, the Commission consults the 
Scientific Committee for Animal Nutrition and the Scientific Committee 
for Food before producing a draft of the Community measures to be adopted 
for the compounds concerned. 
OPINION OF THE COMMITTEES 
Introduction 
The Committees draw the Commission's attention to the fact that the term 
"Methylomonadaceae" has been replaced recently by the term "Methylo-
coccaceae" (cf. Bergey's Manual of Systematic Bacteriology, vol. 1, 
Williams and Wilkins, Baltimore/London 1984). This family of bacteria 
includes various groups of rods, vibrios and cocci having the common 
characteristic of being able to utilize methane as their sole source of 
carbon and energy in earobic conditions. 
Several bacteria of the family can be cultivated to produce edible bio-
proteins. However, the only exhaustive data on performance in livestock 
feeding at present available to the Committees were those concerning 
Pruteen (*), a bioprotein produced by Imperial Chemical Industries PLC, 
the dossiers of which were supplied. Pruteen (*) is obtained by growing 
Methylophilus methylotrophus (synonyms : Pseudomonas methylotropha, 
Methylomonas methylotropha), strain NCIB 10.515, on methanol. (Talbot 
C.J. et al., 1980). 
In the early manufacturing process Pruteen (*) was not treated with 
hydrogen peroxide. The present procedure, which makes use of the treat-
ment of the biomass with hydrogen peroxide before final dessication, was 
initially introduced as a bleaching measure. This treatment results in a 
partial oxidation of methionine to methionine sulphoxide and methionine 
sulphone, and cysteine and cystine to cysteic acid without major changes 
in the nutritional value of Pruteen (*). Of these conversion products, 
only methionine sulphone and cysteic acid, which account for a small pro-
portion, are not bioavailable. 
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The only biologically significant modification noted was that the pero­
xide treated product was better tolerated by the chicken. On the basis 
of their similarity data available on both products have been used in the 
global evaluation of the safety of presently manufactured material. This 
evaluation refers exclusively to the use of Pruteen (*) in animal 
feedingstuffs. The material specified in the submission is not intended 
for human consumption without further processing. 
1. Nutritional value 
Pruteen (*) is marketed in two forms : granules (particle 
diameter : 500 microns) and powder (particle diameter : 25 
microns). Its average crude protein content (Ν χ 6.25) is 72.0 + 2% 
for the granules and 70.3 + 2% for the powder. The product contains 
12.5 g nitrogen/100 g dry matter, of which 19.3% is in the form of 
nucleic nitrogen (13.8 g nucleic acid/100 g dry matter). The nitro­
gen of the cell wall of the bacteria (muramic acid + diaminopimelic 
acid + glucosamine and ethanolamine) represents 2.7% of the total 
nitrogen. The true protein content is 54.7 g per 100 g dry matter. 
The amino acid composition of the protein of the product is (g/16 g 
nitrogen) : lysine 5.7; threonine 4.7; methionine 1.9 and cystine 
0.7. Methionine is the first limiting amino acid in the rat. The 
availibility of lysine, methionine and thryptophan, determined in 
chickens, is respectively 89, 90 and 97 % (Abbey et al. 1980). 
The chemical score of this protein is 59 as against that of the egg, 
44 for soya, 66 for skimmed-milk powder and 74 for good quality 
fishmeal. The biological value of this protein, determined in the 
rat, varies from 66.2 to 76.8%, depending on the experiment. The 
addition to the diet of 0.27» of methionine raises this value to 88.4%. 
- 53 -
Since the average digestibility of this protein is 90 + 2% in the 
rat, pig, calf and poultry, the net protein utilisation (NPU) is at 
least 90% of the biological value. In the rat and pig, the NPU is 
65-70%. This figure is very close to that of soya (71%) but lower 
than that of good quality fishmeal (80%). 
The constitutive fat of Pruteen (*) is accounted for essentially by 
phospholipids. The content in total lipids after addition of soya 
oil in amounts varying according to the form of the product, is of 
8.5 + 1.5% for the granules and 13.2 + 2.0% for the powder. The 
fatty acids are chiefly made up of palmitic and palmitoleic acids. 
Linear fatty acids with an uneven number of carbon atoms are present 
in small quantities. 9, 10-methylene hexadecanoic acid (C 17) is the 
only cyclopropane acid present. According to Steel et al. (1977), 
the level of this acid in granula Pruteen (*) is 0.25% of dry weight, 
i.e. 3.2% of the total fatty acid. No cyclopropene acid has been 
detected. 
The mean digestibility of the fat is 93% in the pig, calf and poultry 
for levels of incorporation of 6.5-37.5 of the ration. Mean 
metabolizable energy content of the product fed to poultry is 
14.38 kJ/kg (Bolton and Blair 1974). 
Pruteen (*) has been tested for its efficacy in numerous trials (Vogt 
et al. 1975, Hinks 1977, Braude et al. 1977, Waterworth and Heath 
1981, Lloyd 1983). 64 trials grouping 194.250 subjects were carried 
out on poultry; 33 trials grouping 4.782 subjects on pigs and 
piglets, 69 trials grouping 8.150 subjects on calves and lambs, and 
16 trials grouping 109.000 subjects on fish. Performances equal and 
sometimes superior to those of fishmeal and soya at isonitrogenous 
levels were obtained in mammals and birds with rations containing 
5-10% of the product and fish with rations containing 30%. 
On the basis of the foregoing information, Pruteen (*) has a good 
nutritional value as a source of protein for feeding to pigs, calves, 
poultry and fish. 
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Evaluation of risks 
2.1. Pathogenicity and hypersensitivity 
The bacterial strain used for the production of Pruteen (*) can 
be differentiated from other methylotrophic strains of the 
family of Methylococcaceae by variations in the composition of 
its cell walls (phospholipids, hydroxylated fatty acids, etc.) 
and DNA, and by its sensitivity towards antibiotics. On the 
other hand, the strain presents similarities to other gram-
negative organisms, particularly E. coli and Salmonella spp., in 
its cell-wall structure. 
On account of the obligate methylotrophic properties of this 
strain, it is reasonable to assume that viable cells which may 
normally escape the fermenter are unlikely to present any 
pathogenic risks for man or animals. This view-point is sup-
ported by the results of experiments carried out on mice by i.p. 
10 12 . injection of 10 -10 viable or dead cells. Animal 
mortalities induced by either viable or dead cells were very 
similar and both significantly lower than mortalities ob- served 
with known pathogenic bacteria such as E. coli, Salmonella spp. 
and Staphylycoccus aureus. Moreover, no microbial proliferation 
was observed in the peritoneal cavity and in the organs of mice 
treated with viable cells. 
Immunological monitoring of workers exposed to Pruteen (*) 
during its production has not revealed any allergic reaction, 
3 although exposure to dust concentrations exceeding 10 mg/m 
resulted in influenza type symptoms and conjunctivitis which 
were probably irritative in nature. These findings stress the 
importance of controlling dust formation during the production, 
distribution and use. This control has been achieved by 
adopting special precautions when granulating or grinding (e.g. 
the addition of soya oil and use of a room with forced 
ventilation). 
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From these data, it emerges that no significant risks exist 
for the health of workers involved in production, distribution 
and use of Pruteen (*) if adequate precautions to prevent 
exposure to dust are taken. 
2.2. Biological and toxicológica! aspects 
2.2.1. Effects in target species 
Feeding studies in pigs extending over 12-20 weeks with un-
treated or hydrogen peroxide treated Pruteen (*) used levels 
ranging from 2.25-30% in the diet. Growth rates and feed in-
take were improved but blood uric acid levels increased 
temporary at the 6.5% level. At higher levels of 
incorporation, feed intake, growth, kidney weights, liver 
weight, and adrenal weights were reduced. A 6-litter three 
generation study showed no pregnancy or litter abnormalities. 
A teratology study using levels of feeding from 8-18% did not 
show adverse effects. The 98-day feeding study with the 
treated-product showed slightly increased kidney weights 
compared to controls at the 30% test level but no histopa-
thological abnormalities associated with this finding. 
Feeding tests in calves extending over 16 weeks with 15-25% 
untreated Pruteen (*) produced no significant toxicological 
effects, although weight gain and feed conversion were 
reduced. Further studies with hydrogen peroxide - treated 
Pruteen (*) showed essentially the same effects (Sedgman, Roy 
and Thomas, 1985; Sedgman et al., 1985). 
Nine different feeding experiments were carried out on 
broilers, layers and breeding hens with untreated or hydrogen 
peroxide-treated Pruteen (*) administered at levels of 2.5 to 
25%. Dose levels above 10% reduced growth and lowered haemo-
globin. At the 25% level liver and spleen weights increased 
as did the activity of the serum transaminases. 
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The livers of female birds developed necrotic and granulo-
matous lesions with the untreated product. Of the avian 
species tested (chickens, turkeys, quails, ducks), only 
chickens developed these hepatic lesions. 
In two 8-week studies in broilers and one study in layers, the 
hydrogen peroxide-treated product did not increase the 
incidence of hepatic lesions at the level of 25% in the diet. 
The reason for this effect of the treatment with hydrogen 
peroxide is not known. Egg production and hatchability were 
not affected. 




From these data, it emerges that Pruteen (*) as it is manu-
factured at present carries no appreciable risks for animal 
health when added at a rate of up to 7% in the diet of pigs, 
10% in the diet of calves and poultry, and 30% in that of fish. 
2.2.2. Effects on the quality of animal products 
The use of Pruteen (*) at the recommended levels of incorpora-
tion (cf. point 2.2.1.) and at higher levels over long periods 
(10-30% for 16-17 weeks in pigs, 20% for 20 weeks in calves, 
30% for 20 weeks in trout, 7.5-30% for more than 50 weeks in 
chickens) hardly alters fatty acid composition in the tissues 
and products of target species. Under the proposed conditions 
of use, the presence of trace amounts of C 17-cyclopropane 
acid was detected by capillary gas chromatography in the 
adipose tissues of pigs (up to 0.10% of total fatty acids) and 
in the egg yolks (0.11% of total fatty acids). No trace of 
the acid was found in the adipose tissues of chicken, calves 
or trout (limit of detection : 0.02% of total fatty acids). 
In pigs, the small quantities of cyclypropane acid are elimi-
nated slowly. In man, degradation by beta and omega oxidation 
is probable (Lindstedt et al. 1974). 
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A comparative study of the technological and organoleptic 
properties of meat and eggs obtained from animals fed with 
Pruteen (*) and from those reared on conventional protein 
sources showed no significant difference. 
2.2.3. Effects in laboratory animals 
Numerous nutritional studies provide evidence that this 
bioprotein is metabolized in the same way as conventional 
proteins. With regard to toxicity studies, traditional 
toxicological tests are difficult to carry out on proteins 
because of the nutritional imbalance induced at high levels of 
incorporation in the diet. For this reason, isonitrogenous 
control diets based on casein were frequently included in the 
studies. 
Four 90-day studies in rats using doses from 3.7-30% of un-
treated Pruteen (*) and two 90-day studies using 15 and 30% of 
the hydrogen peroxide-treated product showed little in the way 
of toxic effects. Serum levels of urea and allantoin, and 
kidney weights were increased in most tests only at doses of 
30%. The slight but consistent decrease in haemoglobin was 
still within the normal range. Corticomedullary nephro-
calcinosis without alteration of the kidney function was noted 
in female rats at doses of 15 and 30% and in male rats at the 
dose of 30%. The peroxide-treated materials was of the same 
toxicity as the untreated one. Several multigeneration 
reproduction tests on the untreated material showed no 
significant effects on reproductive function or litter 
parameters nor were there any teratological effects at 15 and 
30% dietary levels. 
A two-year chronic toxicity/carcinogenicity study using 7.5, 
15 and 30% of untreated Pruteen (*) in the diet showed the 
effects of high protein intake and ionic imbalance at the 
levels of 15 and 30%. No carcinogenic effect was noted. 
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Beagle dogs from 6 weeks to 1 year were fed on a diet contai-
ning untreated Pruteen (*) at 30% and 60% levels and on an 
isonitrogenous casein diet. With the different diets, 
enlarged kidneys with fatty infiltration were observed and 
interpreted as a result of the protein overload. No urinary 
calculi were found. In the males, there was no significant 
difference in incidence between the casein controls and test 
dogs; in the females, dogs fed 60% Pruteen (*) had heavier 
kidneys than those which had been fed the isonitrogenous 
casein diet. 3 dogs out of 8 fed on a 60 % Pruteen (*) based 
diet and 1 dog out of 8 fed on a 30 % diet developed a 
transient weakness of hind limbs. Prolonged treatment produced 
hygromas of elbows and hocks. No cause could be identified. 
Among the species studied, only the dogs were affected and 
these effects appeared to be specific. One single experiment 
was done in Dalmatian dogs; 50 % Pruteen (*) diet raised serum 
urate. 
The product was also submitted to mutagenicity tests. A 
dominant lethal test of untreated Pruteen (*) in mice using 
15 % and 30 % in the diet, but with only 5-day male exposure, 
showed no mutagenic potential. A S. typhimurium reversion 
test, including S 9 metabolic activation, on a neutralised 
alkaline solution of both peroxide-treated and untreated 
material and of an in vitro enzymatic digest, and a mouse 
micronucleus test with the treated material also showed 
negative results. A host-mediated assay on hydrogen 
peroxide-treated product in mice with S. typhimurium TA 1537, 
TA 98 and TA 100 was inconclusive. 
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No mutagenic, carcinogenic or teratogenic effects have been 
observed in the studies reviewed with the product as prepared at 
present. No other adverse effects have been noted in laboratory 
animals if fed up to 7.5 % in the diet, provided the nutritional 
balance is observed. 
3. Conclusions 
In the light of available information, most of which is presented in 
this report, the Committees express the following opinion : 
3.1. Of the protein products obtained from methylotrophic bacteria 
intended to be used as a source of protein in feedingstuffs, 
only Pruteen (*) has so far been the subject of a dossier 
forwarded to the members of the Committees and prepared in 
accordance with the "Guidelines for the assessment of certain 
products used in animal nutrition" (a). This opinion of the 
Committees is therefore limited to the assessment of this 
product. 
3.2. In reply to question 1 of the Commission, the product examined 
has a good nutritional value as a source of protein for feeding 
to pigs, calves, poultry and fish. 
3.3. In reply to question 2 of the Commission the product examined 
- carries no appreciable risks for livestock if the level of 
incorporation does not exceed 7 % in the ration of pigs, 10 % 
in the ration of calves and poultry, and 30 % in that of fish, 
- poses no appreciable risks for the health of workers involved 
in its production, distribution and use if adequate 
precautions are taken to prevent exposure to dust, 
(a) OJ n° L 126, 13.05.1983, p. 23 
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- carries no appreciable risks for the consumer from the 
consumption of products obtained from animals fed with a diet 
containing it. In addition, the characteristics and 
organoleptic properties of such products are not different 
from those of products obtained from animals reared on 
conventional protein sources, 
- which originates from non-pathogenic bacteria, has no 
toxicological effects and is free from any residues of the 
culture medium or harmful contaminants. Its use in animal feed 
does not result in appreciable risks for the environment. 
3.4. The Committees cannot give an opinion on other products obtained 
from bacteria of the family of Methylomonadaceae even if 
cultivated under the same conditions as Pruteen (*), without 
assurance as to the equivalence of the characteristics of such 
products. 
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